Tirzepatide is a medication used for the treatment of type 2 diabetes and obesity. It is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide works by mimicking the effects of these incretin hormones, which help regulate blood sugar levels and reduce appetite.
Dosing of Tirzepatide
Tirzepatide is administered as a once-weekly subcutaneous injection. The dosing regimen usually follows a titration schedule to minimize gastrointestinal side effects and allow the body to adjust to the medication.
Starting Dose:
Typically, the initial dose is 2.5 mg once weekly for the first 4 weeks.
Dose Escalation:
After the initial 4 weeks, the dose is usually increased to 5 mg once weekly.
Based on individual glycemic needs and tolerability, the dose can be further increased in increments (e.g., 7.5 mg, 10 mg, 12.5 mg, up to a maximum of 15 mg once weekly).
Maintenance Dose:
The maintenance dose will vary depending on the patient’s response to the medication and any side effects experienced. The maximum recommended dose is 15 mg once weekly.
Administration:
Tirzepatide is injected subcutaneously in the abdomen, thigh, or upper arm. It is important to rotate the injection sites to reduce the risk of lipodystrophy.
Side Effects:
Common side effects include nausea, vomiting, diarrhea, and decreased appetite. These are usually more pronounced during the initial weeks of treatment and tend to decrease over time.
Monitoring:
Regular monitoring of blood glucose levels, kidney function, and other relevant parameters is recommended to ensure the medication is working effectively and safely.
Contraindications:
Tirzepatide is not recommended for people with a personal or family history of medullary thyroid carcinoma (MTC) or those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
It’s essential to follow your healthcare provider’s guidance for dosing and administration, as individual needs can vary.
Facts and comparison Tirzepatide injection Levocarnitine ResearchGate and PubChem & PubMed – NCBI